Circulating tumor DNA for prognosis in hematologic malignancies receiving immune checkpoint inhibitors or chimeric antigen receptor T-cell therapy: a systematic review and meta-analysis
Circulating tumor DNA (ctDNA) is an emerging biomarker in hematologic malignancies, and elevated ctDNA levels may reflect higher tumor burden. Its prognostic significance in patients undergoing chimeric antigen receptor T-cell (CAR-T) therapy or immune checkpoint inhibitors (ICIs) remains debatable. The purpose of...